Sunshine Biopharma, Inc. (SBFM): Net earnings per share growth forecast for next year
Sunshine Biopharma faces a capital deficit and uncertainty regarding clinical trials. The projected growth in earnings per share for the next fiscal year visualizes these challenges, with 80.20 setting the current value of the metric. However, demand for oncology therapy remains stable regardless of GDP. The business's security is guaranteed by its operations in the US and the humanitarian status of its developments.
SBFM (Sunshine Biopharma, Inc.): analytical breakdowns and indicator data
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- company book value details:
- debt and liquidity data:
Debt to Equity Sunshine Biopharma|SBFM - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Capital Sunshine Biopharma, Inc.|SBFM - Aggregate Debt Obligations|Debts to Book Capitalization Sunshine Biopharma, Inc.|SBFM - Long-Term Debt Volume|Company Short-Term Debt Sunshine Biopharma|Quick Ratio sunshinebiopharma.com
- earnings and market ratios statistics:
SBFM - Company Net Income|Future Profit Sunshine Biopharma|SBFM - Company Value to Net Income|Forward P/E Multiple Sunshine Biopharma, Inc.|SBFM - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Sunshine Biopharma, Inc.|SBFM - Operating income before deduction of amortization|Earnings per share for the last twelve months Sunshine Biopharma|SBFM - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months sunshinebiopharma.com|SBFM - Earnings per share trend in current year|Earnings growth forecast for next year Sunshine Biopharma
- revenue and sales proceeds data:
Fundamental company valuation:sunshinebiopharma.com, SBFM
This indicator measures the dynamics of analysts' consensus earnings per share (EPS) forecasts, allowing investors to differentiate short-term market volatility from fundamental business strengthening. By analyzing the EPS forecast trend for Sunshine Biopharma (SBFM) on the GURU.Markets platform, an investor can see how patent protection and the high margins of SBFM cancer therapies translate into sustainable growth in expected returns and long-term financial stability.
Competitor analysis
ONC (BeiGene Ltd) - Earnings growth forecast for next year|Expected net earnings per share growth next year Halozyme Therapeutics HALO|Net earnings per share growth forecast for next year Revolution Medicines, Inc. (RVMD)|Earnings growth forecast for next year Ascentage Pharma Group International (AAPG)|Earnings growth forecast for next year CGON (CG Oncology Inc)|Expected earnings per share trend next year URGN|bicara.com - Earnings growth forecast for next year|Expected earnings per share trend next year PSNL (personalis.com)|Erasca Inc (ERAS) - Net earnings per share growth forecast for next year|Expected earnings per share growth for next year Delcath Systems|YMAB (YmAbs) - Earnings growth forecast for next year|AURA: Expected earnings per share trend next year|Net earnings per share growth forecast for next year Candel Therapeutics, Inc. (CADL)|Earnings growth forecast for next year Accuray (ARAY)|Net earnings per share growth forecast for next year SELLAS Life Sciences Group Inc. SLS|Actuate Therapeutics, Inc (ACTU) - Expected net earnings per share growth next year|CTOR - Net earnings per share growth forecast for next year|HURA: Net earnings per share growth forecast for next year|TARA (Protara) - Expected earnings per share growth for next year|Fate Therapeutics, Inc. - Expected earnings per share trend next year|WHWK (aadibio.com) - Earnings growth forecast for next year|TCRX: Expected earnings per share trend next year|Net earnings per share growth forecast for next year Champions Oncology (CSBR)|XBiotech - Projected earnings per share growth rate for next year|Net earnings per share growth forecast for next year CEL-SCI CVM|Consensus forecast of earnings per share growth for next year OS Therapies (OSTX)|Radiopharm Theranostics Limited - Earnings growth forecast for next year|Expected net earnings per share growth next year Artiva Biotherapeutics|ANL (adlainortye.com) - Expected earnings per share growth for next year|Expected earnings per share growth for next year Veru Pharma|TPST (Tempest Therapeutics Inc) - Earnings growth forecast for next year|Xilio Therapeutics, Inc. (XLO) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Enochian BioSciences (RENB)|MURA: Net earnings per share change forecast for next year|Earnings growth forecast for next year KAPA (kairospharma.com)|Consensus forecast of earnings per share growth for next year OnKure (OKUR)|CytoMed Therapeutics Ltd - Earnings growth forecast for next year|curis.com (CRIS) - Expected earnings per share growth for next year|Apollomics Corp (APLM) - Net earnings per share growth forecast for next year|Tharimmune - Expected earnings per share trend next year|ADVB (Advanced Biomed Corp) - Earnings growth forecast for next year|Expected earnings per share growth for next year Genprex, Inc (GNPX)|Earnings growth forecast for next year CLDI|Net earnings per share growth forecast for next year XBIO (Xenetic Biosciences, Inc.)|Earnings growth forecast for next year SLRX (salariuspharma.com)|PPBT - Expected earnings per share growth for next year|AONC - Net earnings per share growth forecast for next year|Expected earnings per share trend next year BGNE (BeOne Medicines)|CKPT: Earnings growth forecast for next year|Elevation Oncology Inc. (ELEV) - Earnings growth forecast for next year|ICAD (iCAD) - Earnings growth forecast for next year|Earnings growth forecast for next year ikenaoncology.com|Earnings growth forecast for next year NTBL|Earnings growth forecast for next year Viracta Therapeutics Inc. (VIRX)|Net earnings per share growth forecast for next year MorphoSys Inc MOR|Expected earnings per share trend next year NAYA|AAPGV: Expected earnings per share growth for next year
